Post-licensure Safety Surveillance Study of Menactra Vaccine When Administered As a 2-dose Schedule to Children 9 Months Through 23 Months of Age.
Phase of Trial: Phase IV
Latest Information Update: 16 Nov 2016
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
- Indications Meningococcal infections
- Focus Adverse reactions
- Sponsors Sanofi; sanofi pasteur
- 25 Sep 2016 Status changed from recruiting to completed.
- 25 Sep 2012 New trial record